ABT
Abbott Laboratories · Healthcare
Abbott Laboratories · Healthcare
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Healthcare
Medical - Devices
114,000
1980-03-17
0.78
Stratton John G
director
382 SH @ $0.00
2026-03-31
Roman Michael F
director
367 SH @ $0.00
2026-03-31
Gonzalez Patricia Paola
director
321 SH @ $0.00
2026-03-31
Alpern Robert J
director
76 SH @ $0.00
2026-03-31
Ahuja Nita
director
102 SH @ $0.00
2026-03-31
ORVILLE JACOB A
officer: Senior Vice President
13,255 SH @ $0.00
2026-03-23
ORVILLE JACOB A
officer: Senior Vice President
0 SH @ $0.00
2026-03-23
Shroff Eric
officer: Senior Vice President
1,384 SH @ $116.26
2026-02-27

With chronic disease on the rise, a new survey from Abbott shows information overload, confusion and cost leave many Americans struggling, worrying about how to stay healthy ABBOTT PARK, Ill., April 9, 2026 /PRNewswire/ -- Today, Abbott (NYSE: ABT), a global leader in chronic disease prevention, treatment and care, is releasing new survey findings highlighting a growing tension: 74% of U.S. adults believe most chronic diseases, such as diabetes or cardiovascular disease, are preventable, but only 1 in 4 feel very confident in knowing how to care for their health.

Abbott Laboratories has declined over 16% since my last review, which was previously rated a HOLD, as the valuation was a little rich. The acquisition of Exact Sciences adds a solid piece to a company with a long, proven track record. The segments were kind of a mixed bag in the most recent earnings report, and I'll be monitoring the struggling areas to see where they might go.

CCLA Investment Management decreased its holdings in Abbott Laboratories (NYSE: ABT) by 10.0% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 845,716 shares of the healthcare product maker's stock after selling 94,471 shares during the quarter. CCLA Investment Management's holdings in Abbott

Absolute Software Co. (ABT.TO) (TSE: ABT - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of C$0.00 and traded as high as C$18.26. Absolute Software Co. (ABT.TO) shares last traded at C$18.26, with a volume of 243 shares traded. Absolute Software

In the closing of the recent trading day, Abbott (ABT) stood at $103.56, denoting a +1.7% move from the preceding trading day.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?